

## DAFTAR PUSTAKA

1. Umbas R, Hardjowijoto S, Mochtar CA, Safriadi F, Djatisoesanto W, Soedarso MA, et al. Panduan Penatalaksanaan kanker prostat 2011. Ikatan Ahli Urologi Indonesia. 2011;
2. GEDE RADITYA WISNU WARDHANA, dr. Hanggoro Tri Rinonce, Sp.PA, Ph.D; dr. Sakti R. Brodjonegoro S. KARAKTERISTIK KLINIKOPATOLOGIK HIPERPLASIA PROSTAT JINAK DAN ADENOKARSINOMA PROSTAT DI RSUP DR. SARDJITO YOGYAKARTA. Yogyakarta; 2018.
3. Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid ARAH. Urologic cancer in Indonesia. Japanese journal of clinical oncology. 2015 Aug;45(8):708–12.
4. Stenzel PJ, Schindeldecker M, Tagscherer KE, Foersch S, Herpel E, Hohenfellner M, et al. Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. Translational Oncology. 2020;13(2):336–45.
5. Yeong J, Zhao Z, Lim JCT, Li H, Thike AA, Koh VCY, et al. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas. Journal of Clinical Pathology. 2020 Aug;73(8):463–9.
6. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, et al. The immune



- landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. *Journal of the National Cancer Institute*. 2019;111(3):301–10.
7. Wang Y, Du J, Gao Z, Sun H, Mei M, Wang Y, et al. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. *British Journal of Cancer*. 2023;128(7):1196–207.
  8. Solinas C, Aiello M, Rozali E, Lambertini M, Willard-Gallo K, Migliori E. Programmed Cell Death-Ligand 2: A Neglected But Important Target in the Immune Response to Cancer? *Translational Oncology* [Internet]. 2020;13(10):100811. Available from: <https://doi.org/10.1016/j.tranon.2020.100811>
  9. Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, et al. Tim-3 expression on tumor-infiltrating PD-1+CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma. *Cancer Research*. 2017;77(5):1075–82.
  10. Kahlmeyer A, Stöhr CG, Hartmann A, Goebell PJ, Wullich B, Wach S, et al. Expression of PD-1 and CTLA-4 are negative prognostic markers in renal cell carcinoma. *Journal of Clinical Medicine*. 2019;8(5):1–16.
  11. Heldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, et al. A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic. *European Urology Focus*. 2020;



12. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: A review. *JAMA - Journal of the American Medical Association*. 2017;317(24):2532–42.
13. K. HK, E. MJ, K. TM, A. ST. Random Systematic Versus Directed Ultrasound Guided Transrectal Core Biopsies of the Prostate. *Journal of Urology*. 1989 Jul;142(1):71–4.
14. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27(Kip1) in normal, hyperplastic, and neoplastic cells. *American Journal of Pathology*. 1998;153(3):911–9.
15. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only. 2007;1117–20.
16. Mottet N, Bellmunt J, Briers E, Bergh RCN van den, Bolla M, Casteren NJ van, et al. Guidelines on Prostate Cancer. Update [Internet]. 2015;53(February):31–45. Available from: [http://www.uroweb.org/fileadmin/tx\\_eauguidelines/2005/Pocket/Prostate\\_Cancer.pdf](http://www.uroweb.org/fileadmin/tx_eauguidelines/2005/Pocket/Prostate_Cancer.pdf)
17. Andersen MH. The targeting of immunosuppressive mechanisms in hematological malignancies. *Leukemia* [Internet]. 2014;28(9):1784–92. Available from: <https://doi.org/10.1038/leu.2014.108>
18. Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, et



- al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. *JCI insight*. 2017 Jun;2(11).
19. Wing JB, Ise W, Kurosaki T, Sakaguchi S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. *Immunity* [Internet]. 2014;41(6):1013–25. Available from: <http://dx.doi.org/10.1016/j.immuni.2014.12.006>
20. Turner JS, Benet ZL, Grigorova I. Transiently antigen primed B cells can generate multiple subsets of memory cells. *PLOS ONE* [Internet]. 2017 Aug 29;12(8):e0183877. Available from: <https://doi.org/10.1371/journal.pone.0183877>
21. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. *Annual Review of Immunology* [Internet]. 2008;26(Volume 26, 2008):677–704. Available from: <https://www.annualreviews.org/content/journals/10.1146/annurev.immunol.26.021607.090331>
22. Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, et al. RGMB is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. *Journal of Experimental Medicine* [Internet]. 2014 Apr 21;211(5):943–59. Available from: <https://doi.org/10.1084/jem.20130790>
23. Selenko-Gebauer N, Majdic O, Szekeres A, Höfler G, Guthann E, Korthäuer U, et al. B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is

- Involved in the Induction and Maintenance of T Cell Anergy 1. *The Journal of Immunology* [Internet]. 2003 Apr 1;170(7):3637–44. Available from: <https://doi.org/10.4049/jimmunol.170.7.3637>
24. Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, et al. The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. *OncoImmunology* [Internet]. 2018 Feb 1;7(2):e1390641. Available from: <https://doi.org/10.1080/2162402X.2017.1390641>
  25. Chemistry C, Hospital G. Molecular cloning of human prostate specific antigen cDNA. 1987;214(2):317–22.
  26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods*. 2001;25(4):402–8.
  27. Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *European Urology*. 2022;82(4):399–410.
  28. Yang S, Zhang Q, Liu S, Wang AR, You Z. PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. *American journal of clinical and experimental urology*. 2016;4(1):1–8.
  29. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. *American journal of cancer research*. 2020;10(3):727–42.



30. Wang Z-L, Li G-Z, Wang Q-W, Bao Z-S, Wang Z, Zhang C-B, et al. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. *Oncoimmunology*. 2019;8(2):e1541535.
31. Xue C, Zhu D, Chen L, Xu Y, Xu B, Zhang D, et al. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer. *Translational Cancer Research*. 2019;8(1):111–9.
32. Wang H, Yao H, Li C, Liang L, Zhang Y, Shi H, et al. PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation. *Oncoimmunology*. 2017;6(7):e1327494.